﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 17:17:00 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>XSpray and Cerbios-Pharma announce partnership on the use of XSpray’s RightSize(TM) technology</title><link>http://news.cision.com/xspray-microparticles-ab/r/xspray-and-cerbios-pharma-announce-partnership-on-the-use-of-xspray-s-rightsize-tm--technology,c9298299</link><guid isPermaLink="false">cision1106706</guid><description><![CDATA[Stockholm, Sweden – September 4, 2012. XSpray Microparticles AB today announced a partnership with Cerbios-Pharma SA of Lugano, Switzerland for the joint development of HPAI (High Potency Active Ingredients). HPAI development will be provided by XSpray in Stockholm, while the cGMP production for clinical and commercial use will be carried out at Cerbios in Lugano.
“We are very pleased with this partnership. We believe that RightSize™ technology offers significant advantages in the development of HPAIs”, commented XSpray’s CEO, Dr. Per Andersson. “This partnership is an important step towards]]></description><pubDate>Tue, 04 Sep 2012 10:00:00 GMT</pubDate></item></channel></rss>